One of the frustrations of being a working journalist and a blogger is that, when a big blog-story breaks, you're likely already to be working on something else. And so it is, unfortunately, with NDM-1: I'm on a magazine assignment and will be off interviewing people when I should be blogging.
(This s a great time to recommend that, for any breaking infectious disease news, you follow Crof at H5N1 (@crof) and Michael Coston at Avian Flu Diary (@Fla_Medic), who are dedicated, thoughtful, nimble and smart.)
Since I last posted, there's been lots of additional coverage of the "Indian superbug." Much of it, blog and media, is just echo chamber cannibalizing of the earliest reports (including but certainly not only mine), but there are some important new developments worth noting, which I'll list below.
There are also some important points that are getting lost in the echo-chamber bounce: First, it is not correct to say that every person who acquired this was seeking cheap medical care or engaged in medical tourism; a few of them were treated on an emergency basis while traveling, and a few have no apparent healthcare tie. So this is not a situation of people seeking to save money and, as some commenters seem to be suggesting, receiving their karmic payback. (C'mon: Seriously?) Second, it is also not correct to say that every case of this has been linked to a hospital — it's quite clear in the Lancet ID paper that in South Asia, a number of the cases were community infections. So it is not just a case of hospitals that are dirty or have poor infection control (which by the way is a problem in the US as well, right?); NDM-1 is already a community bug, which will make detection and defense much more complex.
OK, curated list:
First, if you're interested in more from me, CNBC asked me to write up a piece about NDM-1, which ran Thursday; and Friday morning I was on the WNYC-FM (and nationally syndicated) radio show The Takeaway.
Second, the list of potential victims of NDM-1 is growing. Most of them have survived, so marking their cases is really a way of measuring the resistance factor's previously undetected spread:
The UK has released a new statement, updating its earlier warning, and says it has found "around 50" cases carrying NDM-1, an update from the Lancet ID paper. (Side note: This statement, and the earlier warnings, came from the UK's Health Protection Agency. The UK has just announced that it will be shutting down that agency in a cost-cutting measure. Great timing.)
The government of Hong Kong has announced that it has seen one case of NDM-1, but the patient recovered.
Canada has disclosed that it has had two cases, not the one mentioned in the Lancet ID editorial, in two different provinces.
Australia says that it has had three cases scattered across the country.
Belgium has announced one death.
And finally — sadly but probably not surprisingly — India is objecting to the stigma of being characterized as the source of NDM-1. The study's first author has disassociated himself from the paper and members of the government are claiming a "pharma conspiracy." Medical tourism has become a significant industry in India, and it is true some of these reports cast doubt on its safety. But still, I find this reaction disappointing.
Evading the stigma of an emerging disease is not a new impulse: Recall how the government of China suppressed for 6 months the news of the start of the SARS epidemic. They did not stop the epidemic, of course — it eventually sicked more than 8000 people across the globe and killed about 775 — but their suppression of the details of its spread kept other jurisdictions from mounting a defense in time. From my teaching gigs in Hong Kong I can testify how much bitterness endures in Hong Kong over this.
China's actions in 2002-03 led to the enactment of the new International Health Regulations by the WHO, which specify that, because expanding epidemics take no notice of borders, it is inappropriate for any government to attempt to impede the free flow of information about their spread. India is a signatory to the IHRs.
I am not suggesting that India is attempting any suppression of news about NDM-1 — there's no evidence of that — but the volatile language being used does concern me. I acknowledge that India is an extremely open society, with degrees of political expression that can sound surprising from this distance. But let's hope the government takes its commitment to the IHRs as seriously as any signatory should.
Maryn – I loved your book and really appreciate the clarity and timeliness of your blog posts.
The LA Times is reporting ( http://www.latimes.com/health/boostershots/la-heb-superbug-20100813,0,2420404.story) that the news on NDM-1 is overblown. But what really surprised me in their article was this – after mentioning two older antibiotics (colistin and Tygacil), they say: “Pharmaceutical companies are also developing a number of other new antibiotics, a market that is currently viewed as potentially lucrative.”
The “potentially lucrative” part goes against everything I’ve read. I was wondering if that agrees with what you know. It would be good news if it’s true.
Jan - thanks for visiting and for the nice note! Regarding the LATimes story: I too find that puzzling and would like ot know what it is based on. Mind you, there are certainly some companies that find the field lucrative enough to stay in in - for instance, Cubist, who make daptomycin. (The story of the development of daptomycin is told in Superbug the book.) And it is also true that there are small biotechs working on new compounds and hoping for the big score. But overall, there are fewer companies making antibiotics than there used to be, which is why we are in the dry-pipeline situation we now are in, particularly for Gram-negatives.
Can you please explain the difference between VRE and enterrococcus with NDM-1?
I also want to compliment you on the LA times article - you write so well, for so many audiences!
Michele Bruer RN, MSN, MTS
This looks like media hype on the name of India...and it's disgusting but not surprising.
Post a Comment